Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway

Oncotarget

Volumn 6, Issue 41, 2015, Pages 43605-43619

  Li, Li ^a   Huang, Wenting ^a   Li, Kunlin ^a   Zhang, Kejun ^a   Lin, Caiyu ^a   Han, Rui ^a   Lu, Conghua ^a   Wang, Yubo ^a   Chen, Hengyi ^a   Sun, Fenfen ^a   He, Yong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

EGFR TKI; Metformin; Pulmonary fibrosis; TGF

Indexed keywords

ALPHA ACTIN; ANTIDIABETIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; KI 67 ANTIGEN; METFORMIN; PROTEIN TYROSINE KINASE INHIBITOR; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BLEOMYCIN; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLEOMYCIN INDUCED PULMONARY FIBROSIS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; FLOW CYTOMETRY; GEFITINIB INDUCED EXACERBATION OF PULMONARY FIBROSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; MALE; MTT ASSAY; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; INTERSTITIAL LUNG DISEASE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLEOMYCIN; BLOTTING, WESTERN; EPITHELIAL-MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG DISEASES, INTERSTITIAL; MALE; METFORMIN; PULMONARY FIBROSIS; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84952929240     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6186     Document Type: Article

References (34)

1. Soria JC, Mok TS, Cappuzzo F, Janne PA. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer treatment reviews. 2012; 38:416-30.
2. Nguyen KS, Neal JW. First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics: targets & therapy. 2012; 6:337-45.
3. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003; 361:137-9.
4. Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2010; 5:179-84.
5. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. American journal of respiratory and critical care medicine. 2008; 177:1348-57.
6. Nakagawa K, Kudoh S, Ohe Y, Johkoh T, Ando M, Yamazaki N, et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2012; 7:1296-303.
7. Cohen MH, Johnson JR, Chattopadhyay S, Tang S, Justice R, Sridhara R, et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist. 2010; 15:1344-51.
8. Tatler AL, Jenkins G. TGF-beta activation and lung fibrosis. Proceedings of the American Thoracic Society. 2012;9:130-6.
9. Massague J, Chen YG. Controlling TGF-beta signaling. Genes & development. 2000; 14:627-44.
10. Coker RK, Laurent GJ, Shahzeidi S, Lympany PA, du Bois RM, Jeffery PK, et al. Transforming growth factorsbeta 1,-beta 2, and-beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. The American journal of pathology. 1997; 150:981-91.
11. Coker RK, Laurent GJ, Jeffery PK, du Bois RM, Black CM, McAnulty RJ. Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung. Thorax. 2001; 56:549-56.
12. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. The Journal of clinical investigation. 1997; 100:768-76.
13. Bonniaud P, Margetts PJ, Ask K, Flanders K, Gauldie J, Kolb M. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. Journal of immunology. 2005; 175:5390-5.
14. Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, et al. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. American journal of respiratory and critical care medicine. 2005; 171:889-98.
15. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, et al. Induction of epithelialmesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. The American journal of pathology. 2005; 166:1321-32.
16. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA. 2006; 103:13180-5.
17. Zavadil J, Bottinger EP. TGF-beta and epithelial-tomesenchymal transitions. Oncogene. 2005; 24:5764-74.
18. Phan SH. Biology of fibroblasts and myofibroblasts. Proceedings of the American Thoracic Society. 2008; 5:334-7.
19. Knight DA, Ernst M, Anderson GP, Moodley YP, Mutsaers SE. The role of gp130/IL-6 cytokines in the development of pulmonary fibrosis: critical determinants of disease susceptibility and progression? Pharmacology & therapeutics. 2003; 99:327-38.
20. Moodley YP, Misso NL, Scaffidi AK, Fogel-Petrovic M, McAnulty RJ, Laurent GJ, et al. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. American journal of respiratory cell and molecular biology. 2003; 29:490-8.
21. Ishiguro Y, Ishiguro H, Miyamoto H. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Up-regulates Interleukin-6 in Cancer Cells and Induces Subsequent Development of Interstitial Pneumonia. Oncotarget. 2013; 4:550-9.
22. Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 2014; 20:2714-26.
23. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA. Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle. 2010; 9:4461-8.
24. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. The European respiratory journal. 2010; 35:496-504.
25. Namba T, Tanaka K, Hoshino T, Azuma A, Mizushima T. Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis. PLoS One. 2011; 6:e27296.
26. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: A metaanalysis. Cancer epidemiology. 2013.
27. Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, et al. Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines. Clin Cancer Res. 2013; 19:3508-19.
28. Chen H, Yao W, Chu Q, Han R, Wang Y, Sun J, et al. Synergistic effects of metformin in combination with EGFRTKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. Cancer letters. 2015.
29. Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, et al. Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. American journal of respiratory cell and molecular biology. 2009;41: 562-72.
30. Gao Y, Xu X, Ding K, Liang Y, Jiang D, Dai H. Rapamycin inhibits transforming growth factor beta1-induced fibrogenesis in primary human lung fibroblasts. Yonsei medical journal. 2013; 54:437-44.
31. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009; 139:871-90.
32. Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. American journal of respiratory and critical care medicine. 2009; 180:657-65.
33. Wu Z, Yang L, Cai L, Zhang M, Cheng X, Yang X, et al. Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an alpha-smooth muscle actin-Cre transgenic mouse. Respiratory research. 2007; 8:1.
34. Tanaka K, Ishihara T, Azuma A, Kudoh S, Ebina M, Nukiwa T, et al. Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis. American journal of physiology Lung cellular and molecular physiology. 2010; 298:L348-60.